Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial

Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors

(2022) Dennis M. Timmerman et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker

(2021) Kristen C. Kelley et al.   BMC CANCER

Advantages and disadvantages of disulfiram coadministered with popular addictive substances

(2021) Patrycja Kleczkowska et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial

(2021) M. Mego et al.   INVESTIGATIONAL NEW DRUGS

Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents

(2021) Vinodh Kannappan et al.   Frontiers in Molecular Biosciences

Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure: Results of the open-label, single-arm, IGG-02 phase II trial.

(2020) Ugo De Giorgi et al.   JOURNAL OF CLINICAL ONCOLOGY

Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness

(2020) Silvia Schmidtova et al.   Cancer Cell International

A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma

(2019) Jiayi Huang et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II study of avelumab in multiple relapsed/refractory germ cell cancer

(2019) M. Mego et al.   INVESTIGATIONAL NEW DRUGS

Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells

(2019) Silvia Schmidtova et al.   Cancers

Targeting ALDH2 with disulfiram/copper reverses the resistance of cancer cells to microtubule inhibitors

(2018) Nan-nan Wang et al.   EXPERIMENTAL CELL RESEARCH

Identification of cancer-type specific expression patterns for active aldehyde dehydrogenase (ALDH) isoforms in ALDEFLUOR assay

(2018) Lei Zhou et al.   CELL BIOLOGY AND TOXICOLOGY

Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC

(2017) Lauren MacDonagh et al.   Oncotarget

Cancer stem cells and chemoresistance: The smartest survives the raid

(2016) Jihe Zhao   PHARMACOLOGY & THERAPEUTICS

Phase II study of everolimus in refractory testicular germ cell tumors

(2016) Michal Mego et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

A Phase IIb Trial Assessing the Addition of Disulfiram to Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

(2015) H. Nechushtan et al.   ONCOLOGIST

Combination of Paclitaxel, Cisplatin, and Gemcitabine (TPG) for Multiple Relapses or Platinum-Resistant Germ Cell Tumors: Long-Term Outcomes

(2013) Andrea Necchi et al.   Clinical Genitourinary Cancer

Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial

(2012) Anja Lorch et al.   JOURNAL OF CLINICAL ONCOLOGY

Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design

(2011) Darren R. Feldman et al.   CANCER

Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44+CD24lo cancer stem cell phenotype

(2011) James M. Reuben et al.   EUROPEAN JOURNAL OF CANCER